Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
New Contract Expands VA Wound Care Center Access to MolecuLight i:X® and DX™ Point-of-Care Devices that Help Clinicians Manage Infection and Improve...
The company's compliance to SOC 2 Type II demonstrates the suitability of the design and operating effectiveness of its controls relevant to security ...
MolecuLight Victorious in its Efforts to Prove Swift Medical Did Not Merit a Patent TORONTO and ALEXANDRIA, VA, Nov. 21, 2023 /PRNewswire/ -...
Unprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient...
6 Clinical Posters and a Presentation Including New Results of a 1,447 Patient Study Highlights the Breadth of Clinical Benefits of the MolecuLight...
Former Healogics CEO Brings Deep Wound Care Industry Experience to MolecuLight's Rapidly Growing Business TORONTO, July 6, 2023 /PRNewswire/ -...
Results from 211 Facilities Show MolecuLight Imaging is a Valuable Tool in Improving Bacterial Infection Management TORONTO, May 23, 2023...
Wide-Spread Clinical Evidence using the MolecuLight Imaging Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care TORONTO ...
Findings show that MolecuLight is an Objective and Equitable Diagnostic Technology Positioned to Help Level Racial Disparity in Wound Care Outcomes...
Successful completion of recent audit demonstrates MolecuLight's commitment to data security TORONTO, April 19, 2023 /PRNewswire/ - MolecuLight Inc., ...
Findings from a New Clinical Study Using MolecuLight Imaging of Diabetic Foot Ulcers Prompts New Diagnostic Terminology Enabling Proactive Infection...
Article is a Follow-On to MolecuLight's Receipt an Innovative Technology Contract from Vizient Last Year PITTSBURGH, Dec. 6, 2022 /PRNewswire/ -...
Contract Awarded for Products that Bring Improvement to the Health Care Industry PITTSBURGH, Sept. 29, 2022 /PRNewswire/ - MolecuLight Corp., the...
Wide-Spread Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates its Significant Global Adoption and Proven Utility in Wound...
New Financing to Meet Significant Growth in Global Demand for MolecuLight's i:X® and DX™ Point-of-Care Imaging Devices for the Wound Care Industry...
Study Confirms the Utility of MolecuLight to Inform Clinicians to the Presence and Location of Clinically Significant Bacteria and Improves Treatment ...
TORONTO, July 7, 2022 /PRNewswire/ - MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing...
New FDA Clearance Illustrates the Utility of the i:X to Reliably Detect Clinically Significant Bacteria that Impedes Wound Healing TORONTO, June 29,...
Contract Awarded for Products that Bring Improvement to the Health Care Industry PITTSBURGH, June 14, 2022 /PRNewswire/ - MolecuLight Corp., the...
Authors of International Consensus Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of...
KOVE Inc. to Distribute the MolecuLight Product Suite to Large South Korean Wound Care Market TORONTO and SEOUL, South Korea, April 6, 2022...
Wide-Spread Clinical Evidence using the MolecuLight i:X Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care TORONTO and ...
8 Clinical Posters and a Presentation and Hands-On Workshop Highlights the Breadth of Clinical Benefits of the MolecuLight Device for Wound Care...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.